New hope for ICU patients in Life-Threatening shock
NCT ID NCT07063680
Summary
This study aims to see if adding a drug called argipressin (vasopressin) to standard treatment helps adults in intensive care who have a severe form of shock that isn't responding to the usual first medication. It will test if this combination improves 30-day survival, reduces the need for kidney dialysis, and helps patients recover from shock faster. The trial is a large, Phase 3 study involving 390 patients across multiple hospitals.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH NOREPINEPHRINE-REFRACTORY VASOPLEGIC SHOCK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Dijon Bourgogne
Dijon, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.